UY26854A1 - Agente terapéutico cristalino - Google Patents

Agente terapéutico cristalino

Info

Publication number
UY26854A1
UY26854A1 UY26854A UY26854A UY26854A1 UY 26854 A1 UY26854 A1 UY 26854A1 UY 26854 A UY26854 A UY 26854A UY 26854 A UY26854 A UY 26854A UY 26854 A1 UY26854 A1 UY 26854A1
Authority
UY
Uruguay
Prior art keywords
crystal
therapeutic agent
pyridylsulfonyl
ethylpiperazine
polymorph
Prior art date
Application number
UY26854A
Other languages
English (en)
Spanish (es)
Inventor
Laurence James Harris
Richard Antony Storey
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY26854A1 publication Critical patent/UY26854A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
UY26854A 2000-07-28 2001-07-26 Agente terapéutico cristalino UY26854A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
UY26854A1 true UY26854A1 (es) 2002-02-28

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26854A UY26854A1 (es) 2000-07-28 2001-07-26 Agente terapéutico cristalino

Country Status (45)

Country Link
EP (1) EP1305314B1 (enExample)
JP (1) JP2004505087A (enExample)
KR (1) KR100457937B1 (enExample)
CN (1) CN1207297C (enExample)
AP (1) AP1400A (enExample)
AR (1) AR032628A1 (enExample)
AT (1) ATE286901T1 (enExample)
AU (2) AU2001272690B2 (enExample)
BG (1) BG107266A (enExample)
BR (1) BR0112734A (enExample)
CA (1) CA2417264C (enExample)
CZ (1) CZ2003126A3 (enExample)
DE (1) DE60108398T2 (enExample)
DO (1) DOP2001000217A (enExample)
DZ (1) DZ3364A1 (enExample)
EA (1) EA004681B1 (enExample)
EC (1) ECSP034454A (enExample)
EE (1) EE200300045A (enExample)
ES (1) ES2231521T3 (enExample)
GE (1) GEP20053494B (enExample)
HR (1) HRP20030061A2 (enExample)
HU (1) HUP0302982A3 (enExample)
IL (1) IL153226A0 (enExample)
IN (1) IN2002MU01649A (enExample)
IS (1) IS6626A (enExample)
MA (1) MA26931A1 (enExample)
MX (1) MX233602B (enExample)
MY (1) MY117831A (enExample)
NO (1) NO324220B1 (enExample)
NZ (1) NZ523226A (enExample)
OA (1) OA12337A (enExample)
PA (1) PA8523501A1 (enExample)
PE (1) PE20020277A1 (enExample)
PH (1) PH12001001922B1 (enExample)
PL (1) PL365133A1 (enExample)
PT (1) PT1305314E (enExample)
SK (1) SK572003A3 (enExample)
SV (1) SV2001000570A (enExample)
TN (1) TNSN01112A1 (enExample)
TW (1) TWI285643B (enExample)
UA (1) UA72631C2 (enExample)
UY (1) UY26854A1 (enExample)
WO (1) WO2002010171A1 (enExample)
YU (1) YU4703A (enExample)
ZA (1) ZA200301457B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DK1742950T3 (da) 2004-04-07 2009-03-16 Pfizer Ltd Pyrazolo-[4,3-D]-pyrimidiner
CA2608018C (en) 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1371647B1 (en) * 1998-04-20 2005-07-13 Pfizer Inc. Pyridine-3-carboxylic acid derivatives and their use as intermediates
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
AU7269001A (en) 2002-02-13
DE60108398T2 (de) 2005-12-22
MX233602B (es) 2006-01-10
OA12337A (en) 2006-05-15
MA26931A1 (fr) 2004-12-20
MY117831A (en) 2004-08-30
PL365133A1 (en) 2004-12-27
YU4703A (sh) 2006-01-16
IL153226A0 (en) 2003-07-06
HRP20030061A2 (en) 2003-04-30
MXPA03000856A (es) 2003-06-06
KR100457937B1 (ko) 2004-11-20
AR032628A1 (es) 2003-11-19
BG107266A (bg) 2003-07-31
TWI285643B (en) 2007-08-21
ES2231521T3 (es) 2005-05-16
NZ523226A (en) 2003-07-25
HUP0302982A3 (en) 2005-01-28
DOP2001000217A (es) 2002-10-30
NO324220B1 (no) 2007-09-10
UA72631C2 (uk) 2005-03-15
KR20030016430A (ko) 2003-02-26
EE200300045A (et) 2004-12-15
CZ2003126A3 (cs) 2004-02-18
IN2002MU01649A (enExample) 2004-12-11
PH12001001922B1 (en) 2006-11-21
AP1400A (en) 2005-04-28
JP2004505087A (ja) 2004-02-19
DE60108398D1 (de) 2005-02-17
HUP0302982A2 (hu) 2003-12-29
EP1305314B1 (en) 2005-01-12
EP1305314A1 (en) 2003-05-02
WO2002010171A1 (en) 2002-02-07
ECSP034454A (es) 2003-03-10
EA200300079A1 (ru) 2003-06-26
SV2001000570A (es) 2002-09-03
CN1207297C (zh) 2005-06-22
GEP20053494B (en) 2005-04-25
AU2001272690B2 (en) 2005-12-08
BR0112734A (pt) 2004-08-10
EA004681B1 (ru) 2004-06-24
SK572003A3 (en) 2004-05-04
NO20030416D0 (no) 2003-01-27
DZ3364A1 (fr) 2002-02-07
NO20030416L (no) 2003-02-05
IS6626A (is) 2002-11-18
HK1055954A1 (en) 2004-01-30
PT1305314E (pt) 2005-04-29
AP2001002234A0 (en) 2001-09-30
PA8523501A1 (es) 2002-10-24
CN1444585A (zh) 2003-09-24
PE20020277A1 (es) 2002-05-11
ATE286901T1 (de) 2005-01-15
TNSN01112A1 (fr) 2005-11-10
CA2417264C (en) 2007-06-12
ZA200301457B (en) 2004-04-28
CA2417264A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
DE60112974D1 (en) Carbolinderivate
DE60236102D1 (en) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
EE200300497A (et) Pürasoolderivaadid HIV raviks
DE60130555D1 (de) 1-(heteroaryl-phenyl)-kondensierte pyrazol-derivate als factor xa inhibitoren
DE69925133D1 (de) Pyrrolobenzodiazepine
NO20042635L (no) 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
MXPA03006224A (es) Inhibidores de cruzipaina y otras proteasas de cisteina.
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
MXPA02012076A (es) Compuestos quimicos.
SE0101932D0 (sv) Pharmaceutical combinations
AU2001266575A1 (en) Chemical compounds
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
MXPA03002911A (es) Compuestos quimicos.
DK1557415T3 (da) Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
HUP0400195A3 (en) Imidazole derivatives for modulatig sodium channels, pharmaceutical compositions containing them and use of imidazole derivatives for producing pharmaceutical compositions having sodium channels modulating effect
MXPA03009750A (es) Compuestos quimicos.
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
PT1315492E (pt) Utilização de pirazoles substituídos para o tratamento de alergias
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
MXPA02012472A (es) Compuestos quimicos.
DOP2001000217A (es) Agente terapéutico cristalino
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
CR6856A (es) Agente terapeutico cristalino
NZ504614A (en) Echinocandin derivatives and application as anti-fungal agents
PY0117546A (es) Agente terapeutico cristalino

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140519